Fragile X targeted pharmacotherapy: lessons learned and future directions

Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drug...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Neurodev Disord
Huvudupphovsmän: Erickson, Craig A., Davenport, Matthew H., Schaefer, Tori L., Wink, Logan K., Pedapati, Ernest V., Sweeney, John A., Fitzpatrick, Sarah E., Brown, W. Ted, Budimirovic, Dejan, Hagerman, Randi J., Hessl, David, Kaufmann, Walter E., Berry-Kravis, Elizabeth
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2017
Ämnen:
Review
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467059/
https://ncbi.nlm.nih.gov/pubmed/28616096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s11689-017-9186-9
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk